menu
    • menu
    [{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Allopregnanolone","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Relmada Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Relmada Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Allopregnanolone

    Menu

    Allopregnanolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asarina Pharma

                            Sweden arrow
                            The Generic Rx Session
                            Not Confirmed

                            Asarina Pharma

                            Sweden arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Relmada Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Relmada Acquires Tourette Therapy from Asarina Pharma

                            Details : Relmada acquires Isoallopregnanolone (sepranolone) from Asarina. Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), being evaluated for Tourette syndrome.

                            Product Name : Isoallopregnanolone

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 06, 2025

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Relmada Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech to Advance LYT-300 (Oral allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postp...

                            Details : LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.

                            Product Name : LYT-300

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 14, 2023

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Recepto...

                            Details : LYT-300 is a clinical therapeutic candidate that is in development as a potenƟal treatment for a range of neurological and neuropsychological condions. Developed using PureTech's Glyph™ technology plaƞorm, LYT-300 is an oral prodrug of natural allopr...

                            Product Name : LYT-300

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 19, 2022

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LY...

                            Details : LYT-300 is an oral prodrug of natural allopregnanolone candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions. Developed using PureTech's Glyph technology platform.

                            Product Name : LYT-300

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 14, 2022

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            PureTech Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Tre...

                            Details : LYT-300 (Oral Allopregnanolone), is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline.

                            Product Name : LYT-300

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2021

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Asarina Pharma

                            Sweden arrow
                            PharmScience R&D
                            Not Confirmed

                            Asarina Pharma

                            Sweden arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Asarina Pharma Reports Topline Results from Phase Iib Study in PMDD

                            Details : Substantial reduction in PMDD symptoms was achieved across the patient population, but, in comparison to placebo, primary and secondary endpoints were not statistically significant.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 21, 2020

                            Lead Product(s) : Allopregnanolone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth